主要文件

查看所有文档

SML2287

泊沙康唑标准液

Name: 泊沙康唑标准液
Brand: SIGMA

≥98% (HPLC), lanosterol 14α-demethylase inhibitor, powder

别名:

泊沙康唑标准液溶液, 2,5-脱水-1,3,4-丁氧基-2-C-(2,4-二氟苯基)-4-[[4-[4-[4-[1-[(1S,2S)-1-]乙基-2-羟丙基] -1,5-二氢-5-氧代-4H-1,2,4-三唑-4-基]苯基] -1-哌嗪基]苯氧基]甲基] -1-(1H-1, 2,4-三唑-1-基)-D-苏糖醇, Sch 56592

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₃₇H₄₂F₂N₈O₄

化学文摘社编号:

171228-49-2

分子量:

700.78

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD00941162

Assay:

≥98% (HPLC)

Form:

powder

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

泊沙康唑标准液, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -24 to -32°, c = 1.0 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

Fc1c(ccc(c1)F)[C@@]3(OC[C@H](C3)COc4ccc(cc4)N5CCN(CC5)c6ccc(cc6)N7C=NN(C7=O)[C@H]([C@@H](O)C)CC)C[n]2ncnc2

InChI

1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1

InChI key

RAGOYPUPXAKGKH-XAKZXMRKSA-N

说明

Application

泊沙康唑用于：

土曲霉抗真菌药敏试验
作为羊毛甾醇14α-脱甲基酶 (CYP51) 特异性抑制剂，研究其对白色念珠菌细胞膜通透性的影响
研究其对前鞭毛体的影响

Biochem/physiol Actions

泊沙康唑是一种高效的广谱抗真菌剂，可抑制念珠菌引起的酵母菌感染。它通过抑制羊毛甾醇14α-脱甲基酶 (CYP51)阻断真菌生长。与其他抗真菌唑类药物相反，泊沙康唑据报道不会诱导外排泵机制。泊沙康唑对各类南美锥虫病的病原体克氏锥虫菌株具有抑制作用。

Still not finding the right product?

Explore all of our products under 泊沙康唑标准液

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Chiung-Kuang Chen et al.

PLoS neglected tropical diseases, 4(4), e651-e651 (2010-04-14)

Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other

The use of posaconazole against Chagas disease.

Israel Molina et al.

Current opinion in infectious diseases, 28(5), 397-407 (2015-07-24)

The current therapeutic scenario against Chagas disease has been recently updated with the use of the triazoles in clinical trials and several experimental assays (in-vitro and in-vivo models) which are bringing novel and promising evidence for the treatment of Chagas

Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

Galina I Lepesheva et al.

The Journal of biological chemistry, 285(33), 25582-25590 (2010-06-10)

Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions of people and remains incurable in its chronic stage. The antifungal drug posaconazole that blocks sterol biosynthesis in the parasite is the only compound entering clinical trials

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML2287-25MG	04061835307159
SML2287-5MG	04061835307166